- Sections
- C - Chimiemétallurgie
- C07C - Composés acycliques ou carbocycliques
- C07C 313/06 - Sulfinamides
Détention brevets de la classe C07C 313/06
Brevets de cette classe: 61
Historique des publications depuis 10 ans
|
4
|
6
|
4
|
5
|
6
|
6
|
6
|
9
|
2
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Peloton Therapeutics, Inc. | 38 |
4 |
| Nikang Therapeutics, Inc. | 108 |
4 |
| Orsobio, Inc. | 18 |
4 |
| Novartis AG | 10251 |
3 |
| Vitae Pharmaceuticals, Inc. | 87 |
3 |
| Oxford Drug Design Limited | 11 |
3 |
| Boehringer Ingelheim International GmbH | 4493 |
2 |
| Alkermes Pharma Ireland Limited | 254 |
2 |
| Cytokinetics, Inc. | 251 |
2 |
| Gilgamesh Pharmaceuticals, Inc. | 62 |
2 |
| Piramal Pharma Limited | 55 |
2 |
| Genentech, Inc. | 4110 |
1 |
| Bayer Intellectual Property GmbH | 2363 |
1 |
| FUJIFILM Corporation | 30516 |
1 |
| Ricoh Company, Ltd. | 13333 |
1 |
| ABX Advanced Biochemical Compounds GmbH | 12 |
1 |
| Amira Pharmaceuticals, Inc. | 66 |
1 |
| Arbutus Biopharma Corporation | 161 |
1 |
| Kinex Pharmaceuticals, LLC | 9 |
1 |
| Nanjing University | 800 |
1 |
| Autres propriétaires | 21 |